Last updated on December 2018

Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology Triggers and Outcome


Brief description of study

BACKGROUND: In industrialized countries a considerable and increasing proportion of strokes occur at younger ages. Stroke at young age causes marked disability at worst and thus long-standing socioeconomic consequences and exposes survivors for 4-fold risk of premature death compared with background population. Up to 50% of young patients with ischemic stroke remain without definitive etiology for their disease despite extensive modern diagnostic work-up (i.e. cryptogenic stroke). The group of cryptogenic strokes includes those with patent foramen ovale (PFO) or other abnormalities in the atrial septum in the heart as the only or concomitant finding. Population prevalence of PFO is high, 25%, and the mechanisms how PFO would be associated causally with ischemic stroke remain to be clarified. Moreover, there are only scarce data on clinical outcome, long-term risk of new vascular events, and prevention of such events in these patients.

DESIGN: Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome (SECRETO) is an international prospective multicenter case-control study of young adults (age 18-49) presenting with an imaging-positive first-ever ischemic stroke of undetermined etiology (aim N=2000). Patients are included after standardized diagnostic procedures (brain MRI, imaging of intracranial and extracranial vessels, cardiac imaging, and screening for coagulopathies) and age- and sex-matched to healthy controls in a 1:1 fashion. Up to 45 study sites worldwide will be needed to recruit the planned participant population during a 3-year period. Neurovascular imaging and echocardiography studies, and ECGs will be read centrally.

AIMS: SECRETO involves five principal fields of investigation: (1) Stroke triggers and clinical risk factors; (2) Long-term prognosis (new vascular events, functional and psychosocial outcomes); (3) Abnormalities of thrombosis and hemostasis; (4) Biomarkers of e.g. inflammation, atherogenesis, endothelial function, thrombosis, platelet activation, and hemodynamic stress to characterize postulated cryptogenic stroke mechanisms; and (5) genetic study, including genome-wide association and candidate gene studies as well as next-generation sequencing approach. All analyses consider cardiac functional and interatrial structural properties as a possible mediator. Furthermore, SECRETO Family Study (substudy) aims at collecting extensive family history of thrombotic events from informative patients being screened for SECRETO main study and collect genetic samples from all consenting family members for whole-genome sequencing.

SIGNIFICANCE: SECRETO will provide novel information on clinical and subclinical risk factors, both transient and chronic, predisposing to cryptogenic ischemic stroke in young adults. This study also reveals long-term prognosis of this understudied patient population and may discover new genetic background underlying the disease mechanism and provide potential targets for drug development.

Clinical Study Identifier: NCT01934725

Contact Investigators or Research Sites near you

Start Over

Sylvain Lanthier, MD, OD, CSPQ

CHUM - H pital Notre-Dame
Montreal, QC Canada
  Connect »

Janika Kõrv, MD, PhD

Tartu University Hospital
Tartu, Estonia
  Connect »

Jukka Putaala, MD, PhD, MSc

Helsinki University Central Hospital
Helsinki, Finland
  Connect »

Pekka Jäkälä, MD, PhD

Kuopio University Hospital
Kuopio, Finland
  Connect »

Juha Huhtakangas, MD, PhD

Oulu University Hospital
Oulu, Finland
  Connect »

Heikki Numminen, MD, PhD

Tampere University Hospital
Tampere, Finland
  Connect »

Risto O. Roine, Prof.

Turku University Central Hospital
Turku, Finland
  Connect »

Christian Tanislav, MD

University Hospital Giessen
Giessen, Germany
  Connect »

Bettina von Sarnowski, MD, PhD

Ernst-Moritz-Arndt University Medicine
Greifswald, Germany
  Connect »

Armin J Grau, MD, PhD

Klinikum der Stadt Ludwigshafen a. Rh.
Ludwigshafen, Germany
  Connect »

Georgios Tsivgoulis, MD, PhD

"Attikon" Hospital, University of Athens, School of Medicine
Athens, Greece
  Connect »

Alessandro Pezzini, MD

University of Brescia
Brescia, Italy
  Connect »

Marialuisa Zedde, MD, PhD

Arcispedale S. Maria Nuova
Reggio Emilia, Italy
  Connect »

Dalius Jatuzis, Prof.

Vilnius University Hospital Santariskiu klinikos
Vilnius, Lithuania
  Connect »

Frank-Erik de Leeuw, MD, PhD

Radboud University Nijmegen Medical Centre
Nijmegen, Netherlands
  Connect »

Eva Gerdts, Prof.

Haukeland University Hospital
Bergen, Norway
  Connect »

Catarina A. Fonseca, MD, PhD, ...

Hospital Santa Maria
Lisboa, Portugal
  Connect »

Patricia Martinez-Sanchez, MD

La Paz University Hospital
Madrid, Spain
  Connect »

Turgut Tatlisumak, Prof.

Sahlgrenska University Hospital
Gothenburg, Sweden
  Connect »

Nilufer Yesilot Barlas, MD, PhD

Istanbul University Istanbul Faculty of Medecine
Istanbul, Turkey
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.